Renal cell carcinoma Torisel is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors (see section 5.1). Mantle cell lymphoma Torisel is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL) (see section 5.1).
AbbVie announced results from the Phase III RAY (MCL3001) trial, which showed Imbruvica (ibrutinib) significantly prolonged progression-free survival (PFS; the...
The Phase III INTORSECT (B1771003) study, evaluating Torisel (temsirolimus), from Pfizer, in patients with advanced Renal Cell Carcinoma whose disease...
Pfizer Inc. announced that the Phase III INTORACT trial (B1771006), evaluating the combination of bevacizumab plus Torisel (temsirolimus) compared with...
The FDA has approved Inlyta (axitinib)from Pfizer to treat patients with advanced kidney cancer (Renal Cell Carcinoma) who have not...
BMS announced that the FDA has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with advanced...
Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.